Daniel, Nebert Daniel Nebert
426 Kettering
Pub Med Articles  

  Google Scholar



Wesleyan University, Middletown, Connecticut, BA, 1956-59, Biology, Chemistry
University of Oregon Medical School, Portland, MS, 1961-64, Biochemistry
University of Oregon Medicine School, Portland, MD, 1959-64, Medicine


1978 Annual Pfizer Lecture, Univ of Vermont, College of Medicine, Burlington VT
1979 Annual Pfizer Lecture, Stanford Univ Med Ctr, Stanford CA
1984 Frank Ayrey Fellow Award in Clinical Pharmacology, United Kingdom
1986 Bernard B Brodie Award on Drug Metabolism, Amer Soc Pharmacol & Exptl Ther, FASEB
1988 Ernst A Sommer Memorial Award, 80th Lecture Series, Oreg Health Sci Univ, Portland OR
1991 Wellcome Visiting Professor, Am Soc Biochem Mol Biol, Univ of So.Dakota Sch Med, Vermillion
1994 Elected to the Rank of AAAS Fellow, Am Assoc Advanc Sci Award, presented in Feb 95 in Atlanta GA
1996 Invited Chair, Session Organizer and Speaker, Workshop on "Pharmacogenetics at the Molecular Level," 9th Intl Congress of Human Genetics, Rio de Janeiro, Brazil
1998 Recipient of the 1998 Univ of Cincinnati Distinguished Research Professorship Award
1999 Recipient of the 1999 Univ of Cincinnati George Rieveschl Jr Award for Distinguished Scientific Research
2001 Keynote Speaker, Penn State Univ Life Sci Consortium’s Colloq, Penn State Sch of Med, Hershey, PA
2001 Plenary Lecture, Annu Mtg of the Joint Chinese-Australian Pathologists, Hong Kong Acad of Medicine, China
2002 Keynote Speaker, Plenary Session “Human Genome: the Aftermath and the Future,” 11th Meeting of the North American International Society for the Study of Xenobiotics (ISSX), Orlando, Florida
2005 Winner of the Society of Toxicology’s Distinguished Lifetime Toxicology Scholar Award, presented during Annual SOT Meeting, New Orleans, Louisiana

Professional Experience

1964-65 Pediatric Intern, UCLA Center for Health Sciences, Los Angeles CA 90024
1965-66 Pediatric Resident II, UCLA Center for Health Sciences, Los Angeles CA
1966-68 Research Associate, National Cancer Institute, NIH, Bethesda MD 20892
1968-71 Senior Investigator, NICHD, NIH, Bethesda MD
1971-74 Head, Section on Developmental Pharmacology, Lab of Biomedical Sciences, NICHD, NIH, Bethesda MD
1975-89 Chief, Lab of Developmental Pharmacology, and Head, Section on Pharmacogenetics, NICHD, NIH Bethesda
1977-83 Attending Clinical Staff (one month each year), Pediatrics Ward, NICHD, NIH, Bethesda MD
1980-89 Adjunct Professor, Department of Pharmacology, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda MD
1981-89 Member of the NIH-Wide Human Genetics Clinical Training Program Faculty for Board Certification in Human Genetics, Bethesda MD
1982-89 Designated by the NIH Director (James Wyngaarden) as US Coordinator for the Medical Genetics Program, of the United States-People's Republic of China Cooperative Medical Health Protocol
1989- Professor, Dept of Environmental Health, Univ of Cincinnati Medical Center, Cincinnati OH 45267-0056
1991- Professor, Dept of Pediatrics & Developmental Biology, Division of Human Genetics, Children's Hospital Medical Center, Elland & Bethesda Avenues, Cincinnati OH 45229-2899
1992-97 Director, Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati OH
1994-98 Associate Director, Physician Scientist Training Program for M.D./Ph.D, College of Medicine, University of Cincinnati Medical Center
1999-2003 National Advisory Environmental Health Sciences Council, NIEHS, Research Triangle NC

Editorial boards:
Chief Editor of 'Human Mutation' Journal

Scientific advisory committees:
National Institute of Child Health and Human Development, Pharmacogenomics & Personalized Medicine Workshop
Annual lecturer at University of Colorado School of Pharmacy Health Sciences Center

Selected Publications

Most Recent Publications
<span style="color:red">(Out of a total of more than 625)</span>

Chen Y, Krishan M, Nebert DW, Shertzer HG. Glutathione-deficient mice are susceptible to TCDD-induced hepatocellular toxicity, but resistant to steatosis. Chem Res Toxicol 2012; 25: 94–100

Stiborová M, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 2012; 125: 345–358

Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of vitamin C deficiency during postnatal development on adult behavior: functional phenotype of Gulo(–/–) knockout mice. Genes Brain Behav 2012; 11: 269–277

Gálvez-Peralta M, He L, Jorge-Nebert LF, Wang B, Miller ML, Eppert BL, Afton S, Nebert DW. ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero. PLoS ONE 2012; 7: e36055

Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(–/–) knockout mice. Neurotoxicol Teratol 2012; 34: 450–457

Nebert DW, Zhang G. Personalized medicine: let's temper expectations. Science 2012; 337: 910

Nebert DW, Hay EB, Gálvez-Peralta M, Li H, Johansson E, Yin C, Wang B, He L, Soleimani M. ZIP14 and ZIP8 zinc/bicarbonate symporters: characterization in Xenopus oocytes of metal uptake and inhibition. Metallomics 2012; 4: 1218–1225

Levová K, Moserova M, Nebert DW, Phillips DH, Frei E, Schmeiser HH, Arlt VM, Stiborová M. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines: effects on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol 2012; 265: 360–367

Fullenkamp AN, Haynes EN, Meloncon L, Succop P, Nebert DW. Perceptions of genetic research in three rural Appalachian Ohio communities. J Community Genet 2013; 4: 9–19

Brocker C, Vasiliou M, Carpenter S, Carpenter C, Zhang Y, Wang X, Kotchoni SO, Wood AJ, Kirch H-H, Kopec&#711;ny' D, Nebert DW, Vasiliou V. Aldehyde dehydrogenase (ALDH) superfamily in plants: gene nomenclature and comparative genomics. Planta, 2013; 237: 189–210

Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120431 (http://dx.doi.org/10.1098/rstb.2012.0431)

Nebert DW, Zhang G, Vesell ES. Genetic risk prediction: individualized variability in susceptibility to toxicants. Annu Rev Pharmacol Toxicol 2013; 53: 355–375

Nebert DW, Vesell ES. Pharmacogenetics and pharmacogenomics. In: Emery & Rimoin’s Principles and Practice of Medical Genetics (Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds), 6th ed, Churchill Livingstone, London, 2013; vol. I, Section I, Chapter 23, in press

Liu MJ, Bao S, Gálvez-Peralta M, Pyle CJ, Rudawsky AC, Pavlovicz RE, Killilea DW, Li C, Nebert DW, Wewers MD, Knoell DL. ZIP8 regulates host defense through zinc-mediated inhibition of NF-&#61547;B. Cell Reports 2013; http://dx.doi.org/10.1016/j.celrep.2013.01.009

Gálvez-Peralta M, Shi Z, Chen J, Miller ML, Nebert DW. Oral benzo[a]pyrene in Cyp1a1/1b1(–/–) double-knockout mouse: microarray analysis during squamous cell tumorigenesis in preputial gland duct. Intl J Cancer 2013; Epub ahead of print, Oct 10

Divanovic S, Dalli J, Jorge-Nebert LF, Flick LM, Gálvez-Peralta M, Boespflug ND, Stankiewicz TE, Fitzgerald JM, Somarathna M, Karp CL, Serhan CN, Nebert DW. Contributions of the three CYP1 monooxygenases to pro-inflammatory eicosanoid and inflammation-resolution lipid-mediator pathways. J Immunol 2013; accepted pending minor revision

Iqbal J, Sun L, Cao J, Yuen T, Bab, I, Leu NA, Wagage S, Hunter C, Nebert DW, Zaidi M, Avadhani NG. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of CYP1 enzymes. Proc Natl Acad Sci USA 2013; in press pending minor revision

Copyright Information © University of Cincinnati, 2012
160 Panzeca Way, Kettering Laboratory, Cincinnati, Ohio 45267-0056
Phone: (513) 558-5439 | Fax: (513) 558-4397 | E-Mail Us